{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:43:30Z","timestamp":1756190610427,"version":"3.28.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Introduction The complex nature of neurocognitive impairment in\n                    schizophrenia has been discussed in light of the mixed effects of antipsychotic\n                    drugs, psychotic symptoms, dopamine D2 receptor blockade, and\n                    intelligence quotient (IQ). These factors have not been thoroughly examined\n                    before.<\/jats:p><jats:p>\n          Methods This study conducted a comprehensive re-analysis of the CATIE data\n                    using machine learning techniques, in particular Conditional Inference Tree\n                    (CTREE) analysis, to investigate associations between neurocognitive functions\n                    and moderating factors such as estimated trough dopamine D2 receptor\n                    blockade with risperidone, olanzapine, or ziprasidone, Positive and Negative\n                    Syndrome Scale (PANSS), and baseline IQ in 573 patients with schizophrenia.<\/jats:p><jats:p>\n          Results The study reveals that IQ, age, and education\n                    consistently emerge as significant predictors across all neurocognitive domains.\n                    Furthermore, higher severity of PANSS-negative symptoms was associated\n                    with lower cognitive performance scores in several domains. CTREE analysis, in\n                    combination with a genetic algorithm approach, has been identified as\n                    particularly insightful for illustrating complex interactions between variables.\n                    Lower neurocognitive function was associated with factors such as age&gt;52\n                    years, IQ&lt;94\/95,&lt;12\/13 education years, and more pronounced negative\n                    symptoms (score&lt;26).<\/jats:p><jats:p>\n          Conclusions These findings emphasize the multifaceted nature of\n                    neurocognitive functioning in patients with schizophrenia, with the\n                    PANSS-negative score being an important predictor. This gives rise to a role in\n                    addressing negative symptoms as a therapeutic objective for enhancing cognitive\n                    impairments in these patients. Further research must examine nonlinear\n                    relationships among various moderating factors identified in this work,\n                    especially the role of D2 occupancy.<\/jats:p>","DOI":"10.1055\/a-2258-0379","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:02:45Z","timestamp":1708646565000},"page":"53-60","source":"Crossref","is-referenced-by-count":5,"title":["Unraveling the Influence of Age, IQ, Education, and Negative Symptoms\n                    on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree\n                    Analysis"],"prefix":"10.1055","volume":"57","author":[{"given":"Xenia M.","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine,\n                    Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasue","family":"Mitsukura","sequence":"additional","affiliation":[{"name":"Department of System Design Engineering, Faculty of Science and\n                    Technology, Keio University Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Bies","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University at Buffalo, Buffalo,\n                    NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine,\n                    Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/schbul\/sbr189","article-title":"Dopamine D2 receptor occupancy and cognition in schizophrenia:\n                    Analysis of the CATIE data","volume":"39","author":"H Sakurai","year":"2013","journal-title":"Schizophr Bull"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in\n                    schizophrenia: A review and meta-analysis","volume":"25","author":"R S Keefe","year":"1999","journal-title":"Schizophr Bull"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and\n                    memory in schizophrenia","volume":"161","author":"M J Minzenberg","year":"2004","journal-title":"Am J Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1176\/ajp.156.9.1336","article-title":"Longitudinal neuropsychological follow-up study of patients with first-episode\n                    schizophrenia","volume":"156","author":"A L Hoff","year":"1999","journal-title":"Am J Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1176\/appi.ajp.2019.19050527","article-title":"Distinct polygenic score profiles in schizophrenia subgroups with different\n                    trajectories of cognitive development","volume":"177","author":"D Dickinson","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.psychres.2016.10.070","article-title":"Predictive value of premorbid IQ, negative symptoms, and age for cognitive and\n                    social functions in Japanese patients with schizophrenia: A study using the\n                    Japanese version of the brief assessment of cognition in schizophrenia","volume":"246","author":"K Akiyama","year":"2016","journal-title":"Psychiatry Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"J A Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"K L Bigos","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling\n                    measurements from the CATIE study","volume":"66","author":"Y Feng","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/0091270010387604","article-title":"Population pharmacokinetic modeling of ziprasidone in patients with\n                    schizophrenia from the CATIE study","volume":"51","author":"A M Wessels","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine D\u2082 receptor occupancy from plasma levels of antipsychotic\n                    drugs: A systematic review and pooled analysis","volume":"31","author":"H Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","article-title":"Estimation of population characteristics of pharmacokinetic parameters from\n                    routine clinical data","volume":"5","author":"L B Sheiner","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1073\/pnas.89.15.7144","article-title":"At least five related, but distinct, hepatitis C viral genotypes exist","volume":"89","author":"T A Cha","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","first-page":"212","article-title":"Dopamine D2\/3 receptor occupancy following dose reduction is\n                    predictable with minimal plasma antipsychotic concentrations: An open-label\n                    clinical trial","volume":"42","author":"S Nakajima","year":"2016","journal-title":"Schizophr Bull"},{"volume-title":"R: A language and environment for statistical computing","year":"2022","author":"R Core Team","key":"ref15"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v028.i05","article-title":"Building Predictive Models in R Using the caret Package","volume":"28","author":"M Kuhn","year":"2008","journal-title":"J Stat Softw"},{"key":"ref17","first-page":"3905","article-title":"Partykit: A modular toolkit for recursive partytioning in R","volume":"16","author":"T Hothorn","year":"2015","journal-title":"J Mach Learn Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"22r14626","DOI":"10.4088\/JCP.22r14626","article-title":"Therapeutic reference range for olanzapine in schizophrenia: Systematic review\n                    on blood concentrations, clinical effects, and dopamine receptor occupancy","volume":"84","author":"K Wesner","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.schres.2009.03.035","article-title":"Symptoms as mediators of the relationship between neurocognition and functional\n                    outcome in schizophrenia: A meta-analysis","volume":"113","author":"J Ventura","year":"2009","journal-title":"Schizophr Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1176\/appi.ajp.2010.10060855","article-title":"A meta-analysis of cognitive remediation for schizophrenia: Methodology and\n                    effect sizes","volume":"168","author":"T Wykes","year":"2011","journal-title":"Am J Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1037\/0022-006X.76.3.491","article-title":"A meta-analysis of controlled research on social skills training for\n                    schizophrenia","volume":"76","author":"M M Kurtz","year":"2008","journal-title":"J Consult Clin Psychol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","article-title":"Longitudinal studies of cognition and functional outcome in schizophrenia:\n                    Implications for MATRICS","volume":"72","author":"M F Green","year":"2004","journal-title":"Schizophr Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/nedt.2006.2.4.531","article-title":"Cognitive deficits and functional outcome in schizophrenia","volume":"2","author":"C R Bowie","year":"2006","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","article-title":"Olanzapine: An updated review of its use in the management of schizophrenia","volume":"61","author":"N Bhana","year":"2001","journal-title":"Drugs"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.euroneuro.2017.11.009","article-title":"Pharmacokinetics of risperidone in different application forms - Comparing\n                    long-acting injectable and oral formulations","volume":"28","author":"G Schoretsanitis","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: A novel antipsychotic agent with a unique human receptor binding\n                    profile","volume":"425","author":"A W Schmidt","year":"2001","journal-title":"Eur J Pharmacol"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2258-0379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:54:42Z","timestamp":1730811282000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2258-0379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":26,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,3,12]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2258-0379","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"type":"print","value":"0176-3679"},{"type":"electronic","value":"1439-0795"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}